The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
|Videos|March 10, 2016
Future Landscape of Antidiabetic Agents for Type 2 Diabetes
Susan Cornell, PharmD, CDE, FAPhA, FAADE forecasts the future landscape for antidiabetic agents recommended as a second-line treatment for type 2 diabetics.
Advertisement
Susan Cornell, PharmD, CDE, FAPhA, FAADE forecasts the future landscape for antidiabetic agents recommended as a second-line treatment for type 2 diabetics.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Related to this article
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5